These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21386847)

  • 1. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.
    Palumbo A; Hauler F; Dziunycz P; Schwager K; Soltermann A; Pretto F; Alonso C; Hofbauer GF; Boyle RW; Neri D
    Br J Cancer; 2011 Mar; 104(7):1106-15. PubMed ID: 21386847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate.
    Fabbrini M; Trachsel E; Soldani P; Bindi S; Alessi P; Bracci L; Kosmehl H; Zardi L; Neri D; Neri P
    Int J Cancer; 2006 Apr; 118(7):1805-13. PubMed ID: 16217760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin.
    Demartis S; Tarli L; Borsi L; Zardi L; Neri D
    Eur J Nucl Med; 2001 Apr; 28(4):534-9. PubMed ID: 11357506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.
    El-Emir E; Dearling JL; Huhalov A; Robson MP; Boxer G; Neri D; van Dongen GA; Trachsel E; Begent RH; Pedley RB
    Br J Cancer; 2007 Jun; 96(12):1862-70. PubMed ID: 17519905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of hypericin-mediated photodynamic therapy in combination with angiogenesis inhibitor bevacizumab using in vivo fluorescence confocal endomicroscopy.
    Bhuvaneswari R; Thong PS; Gan YY; Soo KC; Olivo M
    J Biomed Opt; 2010; 15(1):011114. PubMed ID: 20210440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local eradication of rat colon cancer with photodynamic therapy: correlation of distribution of photosensitiser with biological effects in normal and tumour tissue.
    Barr H; Chatlani P; Tralau CJ; MacRobert AJ; Boulos PB; Bown SG
    Gut; 1991 May; 32(5):517-23. PubMed ID: 2040475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
    Kaspar M; Trachsel E; Neri D
    Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high-affinity human antibody that targets tumoral blood vessels.
    Tarli L; Balza E; Viti F; Borsi L; Castellani P; Berndorff D; Dinkelborg L; Neri D; Zardi L
    Blood; 1999 Jul; 94(1):192-8. PubMed ID: 10381513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice.
    Nilsson F; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2001 Jan; 61(2):711-6. PubMed ID: 11212273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
    Hemmerle T; Neri D
    Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in perfusion of mouse tumours after photodynamic therapy.
    van Geel IP; Oppelaar H; Oussoren YG; Stewart FA
    Int J Cancer; 1994 Jan; 56(2):224-8. PubMed ID: 8314306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.
    Tijink BM; Perk LR; Budde M; Stigter-van Walsum M; Visser GW; Kloet RW; Dinkelborg LM; Leemans CR; Neri D; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1235-44. PubMed ID: 19259661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
    Coltrini D; Ronca R; Belleri M; Zardi L; Indraccolo S; Scarlato V; Giavazzi R; Presta M
    J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular effects of photodynamic therapy.
    Krammer B
    Anticancer Res; 2001; 21(6B):4271-7. PubMed ID: 11908681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro characterisation of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy.
    Conway CL; Walker I; Bell A; Roberts DJ; Brown SB; Vernon DI
    Photochem Photobiol Sci; 2008 Mar; 7(3):290-8. PubMed ID: 18389145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy.
    Castano AP; Liu Q; Hamblin MR
    Br J Cancer; 2006 Feb; 94(3):391-7. PubMed ID: 16421588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker.
    Heath-Engel HM; Lingwood CA
    Angiogenesis; 2003; 6(2):129-41. PubMed ID: 14739619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments.
    Berndorff D; Borkowski S; Moosmayer D; Viti F; Müller-Tiemann B; Sieger S; Friebe M; Hilger CS; Zardi L; Neri D; Dinkelborg LM
    J Nucl Med; 2006 Oct; 47(10):1707-16. PubMed ID: 17015908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8
    Puca E; Probst P; Stringhini M; Murer P; Pellegrini G; Cazzamalli S; Hutmacher C; Gouyou B; Wulhfard S; Matasci M; Villa A; Neri D
    Int J Cancer; 2020 May; 146(9):2518-2530. PubMed ID: 31374124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.
    Carnemolla B; Borsi L; Balza E; Castellani P; Meazza R; Berndt A; Ferrini S; Kosmehl H; Neri D; Zardi L
    Blood; 2002 Mar; 99(5):1659-65. PubMed ID: 11861281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.